SLC Corepressor Complex as A Drug Target (P28325)

Target Name: SLC corepressor complex

NCBI ID: P28325

SLC corepressor complex

Other Name(s): SFMBT1-LSD1-CoREST corepressor complex

SLC Corepressor Complex as A Drug Target

The SLC corepressor complex (SFMBT1-LSD1-CoREST corepressor complex) is a protein complex that plays a crucial role in regulating gene expression in the cell. The SLC corepressor complex is composed of three subunits: SLC corepressor subunit 1 (SFMBT1), SLC corepressor subunit 2 (LSD1), and SLC corepressor subunit 3 (CoREST).

SLC corepressor subunit 1 (SFMBT1) is a N-terminal protein that contains a unique nucleotide-binding oligomerization domain (NBO domain) and a T-loop domain. NBO domains are known for their ability to form a covalent complex with specific nucleotides, such as DNA or RNA, leading to competition for binding to transcription factors. The T-loop domain is involved in the regulation of chromatin structure and function.

SLC corepressor subunit 2 (LSD1) is a covalent subunit that contains a unique nucleotide-binding oligomerization domain (NBO domain) and a N-terminal domain that is involved in the regulation of RNA stability. The NBO domain is capable of forming a covalent complex with specific nucleotides, such as RNA, leading to competition for binding to transcription factors. The N-terminal domain is involved in the regulation of protein stability and may play a role in the regulation of gene expression.

SLC corepressor subunit 3 (CoREST) 鈥嬧?媔s a C-terminal protein that contains a unique nucleotide-binding oligomerization domain (NBO domain) and a C-terminal domain that is involved in the regulation of DNA binding and gene expression. The NBO domain is capable of forming a covalent complex with specific nucleotides, such as DNA, leading to competition for binding to transcription factors. The C-terminal domain is involved in the regulation of protein stability and may play a role in the regulation of gene expression.

The SLC corepressor complex plays a crucial role in regulating gene expression by binding to and modulating the activity of transcription factors. The SLC corepressor complex is known to be a drug target and may be a potential biomarker for various diseases, including cancer.

One of the potential drug targets for the SLC corepressor complex is inhibition of the activity of transcription factors that are known to be interacting with the SLC corepressor complex. For example, inhibition of the activity of the transcription factor, NF-kappa-B, has been shown to reduce the level of gene expression in the SLC corepressor complex. Additionally, inhibition of the activity of the transcription factor, AP-1, has also been shown to reduce the level of gene expression in the SLC corepressor complex.

Another potential drug target for the SLC corepressor complex is inhibition of the activity of the SLC corepressor complex itself. For example, inhibition of the activity of the SLC corepressor complex has been shown to reduce the level of gene expression in the cell. Additionally, inhibition of the activity of the SLC corepressor complex has been shown to increase the level of gene expression in the cell.

The SLC corepressor complex is a complex protein that plays a crucial role in regulating gene expression in the cell. The SLC corepressor complex is known to be a drug target and may be a potential biomarker for various diseases, including cancer. Further research is needed to fully understand the role of the SLC corepressor complex in gene expression and to identify potential drug targets.

Protein Name: SLC Corepressor Complex

The "SLC corepressor complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC corepressor complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets